Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease. Al-Lamee, R., Howard, J. P., Shun-Shin, M. J., Thompson, D., Dehbi, H., Sen, S., Nijjer, S., Petraco, R., Davies, J., Keeble, T., Tang, K., Malik, I. S., Cook, C., Ahmad, Y., Sharp, A. S. P., Gerber, R., Baker, C., Kaprielian, R., Talwar, S., Assomull, R., Cole, G., Keenan, N. G., Kanaganayagam, G., Sehmi, J., Wensel, R., Harrell, F. E., Mayet, J., Thom, S. A., Davies, J. E., & Francis, D. P. Circulation, October, 2018.
abstract   bibtex   
Background: There are no data on how fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are associated with the placebo-controlled efficacy of percutaneous coronary intervention (PCI) in stable single-vessel coronary artery disease. Methods: We report the association between prerandomization invasive physiology within ORBITA (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina), a placebo-controlled trial of patients who have stable angina with angiographically severe single-vessel coronary disease clinically eligible for PCI. Patients underwent prerandomization research FFR and iFR assessment. The operator was blinded to these values. Assessment of response variables, treadmill exercise time, stress echocardiography score, symptom frequency, and angina severity were performed at prerandomization and blinded follow-up. Effects were calculated by analysis of covariance. The ability of FFR and iFR to predict placebo-controlled changes in...
@article{al-18fra,
  title = {Fractional {{Flow Reserve}} and {{Instantaneous Wave}}-{{Free Ratio}} as {{Predictors}} of the {{Placebo}}-{{Controlled Response}} to {{Percutaneous Coronary Intervention}} in {{Stable Single}}-{{Vessel Coronary Artery Disease}}},
  abstract = {Background: There are no data on how fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are associated with the placebo-controlled efficacy of percutaneous coronary intervention (PCI) in stable single-vessel coronary artery disease. Methods: We report the association between prerandomization invasive physiology within ORBITA (Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina), a placebo-controlled trial of patients who have stable angina with angiographically severe single-vessel coronary disease clinically eligible for PCI. Patients underwent prerandomization research FFR and iFR assessment. The operator was blinded to these values. Assessment of response variables, treadmill exercise time, stress echocardiography score, symptom frequency, and angina severity were performed at prerandomization and blinded follow-up. Effects were calculated by analysis of covariance. The ability of FFR and iFR to predict placebo-controlled changes in...},
  language = {EN},
  journal = {Circulation},
  author = {{Al-Lamee}, Rasha and Howard, James P. and {Shun-Shin}, Matthew J. and Thompson, David and Dehbi, Hakim-Moulay and Sen, Sayan and Nijjer, Sukhjinder and Petraco, Ricardo and Davies, John and Keeble, Thomas and Tang, Kare and Malik, Iqbal S. and Cook, Christopher and Ahmad, Yousif and Sharp, Andrew S. P. and Gerber, Robert and Baker, Christopher and Kaprielian, Raffi and Talwar, Suneel and Assomull, Ravi and Cole, Graham and Keenan, Niall G. and Kanaganayagam, Gajen and Sehmi, Joban and Wensel, Roland and Harrell, Frank E. and Mayet, Jamil and Thom, Simon A. and Davies, Justin E. and Francis, Darrel P.},
  month = oct,
  year = {2018},
  keywords = {rct,cv,collaboration,interaction,rct-interpretation,spline-examples}
}

Downloads: 0